<p>Sarepta Therapeutics（納斯達克代碼：SRPT - 獲取免費報告）在週一向投資者發佈的報告中，投資分析師將其目標價格從 28.00 美元下調至 20.00 美元，Benzinga 報道。該券商目前對這家生物技術公司的股票給予 “增持” 評級。摩根大通的目標價格意味着該股票相較於前一交易日收盤價有 42.15% 的潛在上漲空間。</p>
<p>獲取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
<ul>
<li>Sarepta 因死亡事件下跌 42%；市場關注 Solid Biosciences</li>
</ul>
<p>SRPT 曾受到多份研究報告的關注。HC Wainwright 在 6 月 25 日的研究報告中重申了對 Sarepta Therapeutics 股票的 “賣出” 評級。Robert W. Baird 在週四的研究報告中將 Sarepta Therapeutics 的目標價格從 30.00 美元上調至 35.00 美元，並給予該股票 “跑贏大盤” 評級。Cantor Fitzgerald 在 6 月 16 日的研究報告中重申了對 Sarepta Therapeutics 股票的 “中性” 評級。加拿大皇家銀行在週四的研究報告中將 Sarepta Therapeutics 的目標價格從 25.00 美元下調至 23.00 美元，並對該公司設定了 “行業表現” 評級。最後，瑞穗證券在 6 月 18 日的研究報告中將 Sarepta Therapeutics 的目標價格從 85.00 美元下調至 40.00 美元，並對該公司設定了 “跑贏大盤” 評級。一位研究分析師對該股票給予了 “賣出” 評級，十四位分析師給予 “持有” 評級，十一位分析師給予 “買入” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價格為 55.33 美元。</p>
<p><strong>查看我們對 SRPT 的最新分析</strong></p>
<h2>Sarepta Therapeutics 股票下跌 36.0%</h2>
<ul>
<li>製藥行業拋售：3 只 RSI 顯示你不應忽視的股票</li>
</ul>
<p>納斯達克 SRPT 週一開盤價為 14.07 美元。該公司的債務與股本比率為 1.00，流動比率為 4.02，速動比率為 2.46。該股票的市值為 13.8 億美元，市盈率為-5.23，貝塔值為 0.45。Sarepta Therapeutics 的 1 年最低價為 11.95 美元，1 年最高價為 150.48 美元。該公司的 50 日移動平均線為 28.42 美元，200 日移動平均線為 67.58 美元。</p>
<p>Sarepta Therapeutics（納斯達克代碼：SRPT - 獲取免費報告）最近於 5 月 6 日發佈了其財報。這家生物技術公司報告本季度每股收益（EPS）為-3.42 美元，低於市場共識預期的 2.20 美元，差距為 5.62 美元。Sarepta Therapeutics 的淨利潤率為-11.12%，股本回報率為-14.88%。該季度的營業收入為 7.4486 億美元，而分析師預期為 6.8575 億美元。在去年同期，該公司的每股收益為 0.73 美元。Sarepta Therapeutics 本季度的收入同比增長 80.2%。賣方分析師預測，Sarepta Therapeutics 在當前年度的每股收益將達到 2.67 美元。</p>
<h2>機構投資者對 Sarepta Therapeutics 的看法</h2>
<ul>
<li>Solid Biosciences 能否在 DMD 市場挑戰 Sarepta？</li>
</ul>
<p>一些大型投資者最近調整了對該公司的持股。Byrne Asset Management LLC 在第一季度新購入 Sarepta Therapeutics 的股份，價值 30,000 美元。Center for Financial Planning Inc.在第一季度新購入 Sarepta Therapeutics 的股份，價值 31,000 美元。Logan Capital Management Inc.在第四季度新購入 Sarepta Therapeutics 的股份，價值 61,000 美元。Ancora Advisors LLC 在第一季度將其在 Sarepta Therapeutics 的持股增加了 150.0%。Ancora Advisors LLC 目前擁有 500 股該生物技術公司的股票，價值 32,000 美元，此前在上個季度又購買了 300 股。最後，Hurley Capital LLC 在第四季度新購入 Sarepta Therapeutics 的股份，價值 76,000 美元。86.68% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Sarepta Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Sarepta Therapeutics, Inc.是一家商業階段的生物製藥公司，專注於 RNA 靶向治療、基因療法和其他基因治療方式的發現與開發，旨在治療罕見疾病。它提供 EXONDYS 51 注射劑，用於治療具有可進行外顯子 51 跳躍的肌營養不良症（Duchenne）的患者；VYONDYS 53 用於治療具有可進行外顯子 53 跳躍的肌營養不良症患者；AMONDYS 45 用於治療具有確認的肌營養不良症基因突變的患者；以及 ELEVIDYS，一種基於腺病毒相關病毒的基因療法，用於治療 4 至 5 歲有確認肌營養不良症基因突變的步態兒童。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Sarepta Therapeutics</li>
<li>3 只超市股票證明它們仍然不可或缺</li>
<li>Iron Mountain 從其 1 年高點下跌 23%——是否被低估？</li>
<li>10 月值得考慮購買的 3 只股票</li>
<li>3 只 ETF 在一項重大美好法案推出時值得購買</li>
<li>如何最有效地使用 MarketBeat 財報篩選器</li>
<li>隨着比特幣創下新高，這 3 只股票可能會爆炸</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Sarepta Therapeutics 嗎？</h2>
<p>在考慮 Sarepta Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Sarepta Therapeutics 並不在名單上。</p>
<p>雖然 Sarepta Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Sarepta醫療

<p>摩根大通已將 Sarepta Therapeutics（NASDAQ:SRPT）的目標股價從 28.00 美元下調至 20.00 美元，同時維持 “增持” 評級。這個新目標暗示該股票相較於前一交易日收盤價有 42.15% 的潛在上漲空間。其他分析師的觀點各異，評級從賣出到跑贏大盤不等。Sarepta 的股票開盤價為 14.07 美元，市值為 13.8 億美元，市盈率為-5.23。儘管每股收益出現虧損，該公司仍報告了同比 80.2% 的顯著收入增長</p>

<p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price cut by investment analysts at JPMorgan Chase &amp; Co. from $28.00 to $20.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the biotechnology company's stock. JPMorgan Chase &amp; Co.'s target price would indicate a potential upside of 42.15% from the stock's previous close.</p>
<div class="lb-trans"><p>Sarepta Therapeutics（納斯達克代碼：SRPT - 獲取免費報告）在週一向投資者發佈的報告中，投資分析師將其目標價格從 28.00 美元下調至 20.00 美元，Benzinga 報道。該券商目前對這家生物技術公司的股票給予 “增持” 評級。摩根大通的目標價格意味着該股票相較於前一交易日收盤價有 42.15% 的潛在上漲空間。</p>
</div><p>Get <strong>Sarepta Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 因死亡事件下跌 42%；市場關注 Solid Biosciences</li>
</ul>
</div><p>SRPT has been the subject of a number of other research reports. HC Wainwright reaffirmed a &#34;sell&#34; rating on shares of Sarepta Therapeutics in a research report on Wednesday, June 25th. Robert W. Baird lifted their target price on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday. Cantor Fitzgerald reaffirmed a &#34;neutral&#34; rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Royal Bank Of Canada cut their price objective on shares of Sarepta Therapeutics from $25.00 to $23.00 and set a &#34;sector perform&#34; rating for the company in a research report on Thursday. Finally, Mizuho cut their price objective on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday, June 18th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $55.33.</p>
<div class="lb-trans"><p>SRPT 曾受到多份研究報告的關注。HC Wainwright 在 6 月 25 日的研究報告中重申了對 Sarepta Therapeutics 股票的 “賣出” 評級。Robert W. Baird 在週四的研究報告中將 Sarepta Therapeutics 的目標價格從 30.00 美元上調至 35.00 美元，並給予該股票 “跑贏大盤” 評級。Cantor Fitzgerald 在 6 月 16 日的研究報告中重申了對 Sarepta Therapeutics 股票的 “中性” 評級。加拿大皇家銀行在週四的研究報告中將 Sarepta Therapeutics 的目標價格從 25.00 美元下調至 23.00 美元，並對該公司設定了 “行業表現” 評級。最後，瑞穗證券在 6 月 18 日的研究報告中將 Sarepta Therapeutics 的目標價格從 85.00 美元下調至 40.00 美元，並對該公司設定了 “跑贏大盤” 評級。一位研究分析師對該股票給予了 “賣出” 評級，十四位分析師給予 “持有” 評級，十一位分析師給予 “買入” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價格為 55.33 美元。</p>
</div><p><strong>View Our Latest Analysis on SRPT</strong></p>
<div class="lb-trans"><p><strong>查看我們對 SRPT 的最新分析</strong></p>
</div><h2>Sarepta Therapeutics Stock Down 36.0%</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 股票下跌 36.0%</h2>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥行業拋售：3 只 RSI 顯示你不應忽視的股票</li>
</ul>
</div><p>NASDAQ SRPT opened at $14.07 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The stock has a market capitalization of $1.38 billion, a PE ratio of -5.23 and a beta of 0.45. Sarepta Therapeutics has a 1 year low of $11.95 and a 1 year high of $150.48. The business's 50-day moving average is $28.42 and its 200 day moving average is $67.58.</p>
<div class="lb-trans"><p>納斯達克 SRPT 週一開盤價為 14.07 美元。該公司的債務與股本比率為 1.00，流動比率為 4.02，速動比率為 2.46。該股票的市值為 13.8 億美元，市盈率為-5.23，貝塔值為 0.45。Sarepta Therapeutics 的 1 年最低價為 11.95 美元，1 年最高價為 150.48 美元。該公司的 50 日移動平均線為 28.42 美元，200 日移動平均線為 67.58 美元。</p>
</div><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.</p>
<div class="lb-trans"><p>Sarepta Therapeutics（納斯達克代碼：SRPT - 獲取免費報告）最近於 5 月 6 日發佈了其財報。這家生物技術公司報告本季度每股收益（EPS）為-3.42 美元，低於市場共識預期的 2.20 美元，差距為 5.62 美元。Sarepta Therapeutics 的淨利潤率為-11.12%，股本回報率為-14.88%。該季度的營業收入為 7.4486 億美元，而分析師預期為 6.8575 億美元。在去年同期，該公司的每股收益為 0.73 美元。Sarepta Therapeutics 本季度的收入同比增長 80.2%。賣方分析師預測，Sarepta Therapeutics 在當前年度的每股收益將達到 2.67 美元。</p>
</div><h2>Institutional Investors Weigh In On Sarepta Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Sarepta Therapeutics 的看法</h2>
</div><ul>
<li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li>
</ul>
<div class="lb-trans"><ul>
<li>Solid Biosciences 能否在 DMD 市場挑戰 Sarepta？</li>
</ul>
</div><p>A number of large investors have recently modified their holdings of the company. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $30,000. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $31,000. Logan Capital Management Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $61,000. Ancora Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after buying an additional 300 shares in the last quarter. Finally, Hurley Capital LLC acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $76,000. 86.68% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了對該公司的持股。Byrne Asset Management LLC 在第一季度新購入 Sarepta Therapeutics 的股份，價值 30,000 美元。Center for Financial Planning Inc.在第一季度新購入 Sarepta Therapeutics 的股份，價值 31,000 美元。Logan Capital Management Inc.在第四季度新購入 Sarepta Therapeutics 的股份，價值 61,000 美元。Ancora Advisors LLC 在第一季度將其在 Sarepta Therapeutics 的持股增加了 150.0%。Ancora Advisors LLC 目前擁有 500 股該生物技術公司的股票，價值 32,000 美元，此前在上個季度又購買了 300 股。最後，Hurley Capital LLC 在第四季度新購入 Sarepta Therapeutics 的股份，價值 76,000 美元。86.68% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Sarepta Therapeutics</h2>
<div class="lb-trans"><h2>關於 Sarepta Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc.是一家商業階段的生物製藥公司，專注於 RNA 靶向治療、基因療法和其他基因治療方式的發現與開發，旨在治療罕見疾病。它提供 EXONDYS 51 注射劑，用於治療具有可進行外顯子 51 跳躍的肌營養不良症（Duchenne）的患者；VYONDYS 53 用於治療具有可進行外顯子 53 跳躍的肌營養不良症患者；AMONDYS 45 用於治療具有確認的肌營養不良症基因突變的患者；以及 ELEVIDYS，一種基於腺病毒相關病毒的基因療法，用於治療 4 至 5 歲有確認肌營養不良症基因突變的步態兒童。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Sarepta Therapeutics</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Iron Mountain Down 23% From Its 1-Year High—Is It Undervalued?</li>
<li>3 Stocks to Consider Buying in October</li>
<li>3 ETFs to Buy as the One Big Beautiful Bill Rolls Out</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>As Bitcoin Hits New Highs, These 3 Stocks Could Explode</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Sarepta Therapeutics</li>
<li>3 只超市股票證明它們仍然不可或缺</li>
<li>Iron Mountain 從其 1 年高點下跌 23%——是否被低估？</li>
<li>10 月值得考慮購買的 3 只股票</li>
<li>3 只 ETF 在一項重大美好法案推出時值得購買</li>
<li>如何最有效地使用 MarketBeat 財報篩選器</li>
<li>隨着比特幣創下新高，這 3 只股票可能會爆炸</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=SRPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Sarepta Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Sarepta Therapeutics 嗎？</h2>
</div><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Sarepta Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Sarepta Therapeutics 並不在名單上。</p>
</div><p>While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sarepta Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

摩根大通給予 Sarepta Therapeutics（納斯達克股票代碼：SRPT）新的目標價為 20.00 美元